<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3b7b662b-8390-4168-b31e-ba430febc1a1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use IVERMECTIN CREAM safely and effectively.  See full prescribing information for IVERMECTIN CREAM.<br/>IVERMECTIN cream, 1%, for topical use<br/>Initial U.S. Approval: 1996</title>
   <effectiveTime value="20240430"/>
   <setId root="75973e89-a03f-48dd-8fe8-8eafc1938d09"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-2294"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-2294"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="396a58ff-4ef9-4adb-abc2-f194fb3954f1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240502"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72162-2294" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ivermectin</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ivermectin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="45802-102" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8883YP2R6D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IVERMECTIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8883YP2R6D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IVERMECTIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8CRQ2TH63M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL PALMITATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="172F2WN8DV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HIE492ZZ3T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENOXYETHANOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="YRC528SWUY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 20 CETOSTEARYL ETHER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NVZ4I0H58X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITAN MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="45"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72162-2294-2" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210225" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <effectiveTime>
                              <low value="20200413"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240108"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>pale yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="c9817152-4d78-4617-967d-2cc07e542858">
                     <text>formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structural formula.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ee6ebaea-abce-4034-9377-156b97161365">
                     <text>figures 1 and 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figures 1 and 2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="bcdc13de-42d8-416b-beed-451f8bdb5e95">
                     <text>figures 3 and 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figures 3 and 4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_2e6d00c6-4124-4dd1-9794-6f9797d249b9">
                     <text>Figure A and B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="instructions.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3c5332ce-5059-4e01-9d47-0cfb09b46c7e">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure C.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_68b7cb9f-3011-4810-9361-0c9cd4b12d21">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure D.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4da8e534-e881-4d7f-b69f-fef74e2d2f21">
               <id root="5c3ce088-a5b8-4f15-bca1-14d11d339f10"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Ivermectin cream is indicated for the treatment of inflammatory lesions of rosacea.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ivermectin cream is indicated for the treatment of inflammatory lesions of rosacea. (<linkHtml href="#ID_4da8e534-e881-4d7f-b69f-fef74e2d2f21">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_43c56089-bea8-4d6e-939d-e58eb5b47915">
               <id root="4ec92154-4ad3-4ba1-8704-623421778d29"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>Apply to the affected areas of the face once daily. Use a pea-size amount for each area of the face (forehead, chin, nose, each cheek) that is affected. Spread as a thin layer, avoiding the eyes and lips.</paragraph>
                  <paragraph>Ivermectin cream is not for oral, ophthalmic, or intravaginal use.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Apply to the affected areas once daily. (<linkHtml href="#ID_43c56089-bea8-4d6e-939d-e58eb5b47915">2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Not for oral, ophthalmic or intravaginal use. (<linkHtml href="#ID_43c56089-bea8-4d6e-939d-e58eb5b47915">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_3fcfad7d-fcee-459e-8201-f004a591a666">
               <id root="d419500f-bb29-4167-b56c-7927718a465a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Cream, 1%.</paragraph>
                  <paragraph>Each gram of ivermectin cream contains 10 mg of ivermectin in a white to pale yellow cream base. Ivermectin cream is supplied in tubes of 30 g, 45 g and 60 g.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cream, 1% (<linkHtml href="#ID_3fcfad7d-fcee-459e-8201-f004a591a666">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_33ff4f00-04bb-47a0-afcb-2365a58ab0a8">
               <id root="92275282-248d-4aa4-a860-257d26e83060"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#ID_33ff4f00-04bb-47a0-afcb-2365a58ab0a8">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_9e891e87-23a4-4881-b439-4d68254a8859">
               <id root="fd252259-0005-402a-9fc5-c50f218f681d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <effectiveTime value="20221031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>In controlled clinical trials with ivermectin cream the most common adverse reactions (incidence ≤ 1 %) included skin burning sensation and skin irritation. (<linkHtml href="#ID_eee195c8-aa62-4c32-be26-bc1e72ce0da9">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Padagis<sup>®</sup> at 1-866-634-9120 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_eee195c8-aa62-4c32-be26-bc1e72ce0da9">
                     <id root="b7d284fc-c502-4eec-b75c-9eacb22cf482"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>During clinical trials, 2047 subjects with inflammatory lesions of rosacea received ivermectin cream once daily. A total of 1555 subjects were treated once daily for more than 12 weeks, and 519 for approximately one year.</paragraph>
                        <paragraph>Adverse reactions, reported in ≤ 1% of subjects treated with ivermectin cream for at least 3 months in vehicle-controlled clinical trials, included skin burning sensation and skin irritation.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0a0bb573-7207-4b70-9139-6f55c41aa46e">
                     <id root="f7a1ba71-88d9-4a64-8ea8-a9f421eb2eb5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Local adverse reactions: contact dermatitis and allergic dermatitis.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4414769b-0d72-467d-a1c0-72fdcdc768d6">
               <id root="b60da561-f513-40a8-afdc-a495ad32d886"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>In vitro studies have shown that ivermectin cream, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.</paragraph>
               </text>
               <effectiveTime value="20200413"/>
            </section>
         </component>
         <component>
            <section ID="ID_24684493-6f7c-4082-b85e-76fb118c38a8">
               <id root="0823d70e-7c74-4667-b6ff-9f0dcc75b91f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20221031"/>
               <component>
                  <section ID="ID_db8e2a10-39b1-4a77-a2b5-eab7a1e06e25">
                     <id root="3b604ffc-0910-4b10-83fb-3a3557a12787"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>The available data on the use of ivermectin, including ivermectin cream, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. </paragraph>
                        <paragraph>In animal reproduction studies, ivermectin induced adverse developmental outcomes when orally administered to pregnant rats and rabbits during the period of organogenesis at doses 1909 or 354 times the maximum recommended human dose (MRHD), respectively. These orally administered doses were maternally toxic to pregnant rats and rabbits. In a pre-and postnatal developmental study in rats, neonatal toxicity and adverse effects on behavioral development were observed when ivermectin was orally administered to pregnant females during gestation and lactation (<content styleCode="italics">see Data</content>). </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>No adequate and well-controlled trials of ivermectin cream have been conducted in pregnant women. Retrospective observational studies evaluated pregnancy outcomes in over 700 women in various stages of pregnancy who received oral ivermectin for the treatment of soil-transmitted helminths in rural Africa. In an additional, randomized open-label trial, 397 pregnant women in their second trimester received a single dose of oral ivermectin, or ivermectin plus albendazole, for soil-transmitted helminths. When compared with a pregnant, untreated population, no differences in pregnancy outcomes were observed between the treated and untreated populations. These studies cannot definitively establish or exclude any drug-associated risk during pregnancy, because either the timing of administration during gestation was not accurately ascertained or the administration occurred only during the second trimester. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Systemic embryofetal development studies were conducted in rats and rabbits. Oral doses of 1.5, 4, and 12 mg/kg/day ivermectin were administered during the period of organogenesis to pregnant female rats. Maternal death occurred at 12 mg/kg/day [1909 times the MRHD based on area under the curve (AUC) comparison]. Cleft palate occurred in the fetuses from the 12 mg/kg/day (1909 times the MRHD based on AUC comparison) group. No treatment related embryofetal toxicity or malformations were noted at 4 mg/kg/day (708 times the MRHD based on AUC comparison). Oral doses of 0.5, 1.5, 2.5, 3.5 and 4.5 mg/kg/day ivermectin were administered during the period of organogenesis to pregnant female rabbits. Maternal death occurred at doses ≥ 2.5 mg/kg/day (72 times the MRHD based on AUC comparison). Carpal flexure occurred in the fetuses from the 4.5 mg/kg/day (354 times the MRHD based on AUC comparison) group. Fetal weight decrease was noted at 3.5 mg/kg/day (146 times the MRHD based on AUC comparison). No treatment related embryofetal toxicity or malformations were noted at 2.5 mg/kg/day (72 times the MRHD based on AUC comparison). </paragraph>
                        <paragraph>A pre- and postnatal development study was conducted in rats. Oral doses of 1, 2 and 4 mg/kg/day ivermectin were administered to pregnant female rats during gestational days 6-20 and lactation days 2-20. Neonatal death occurred at doses ≥ 2 mg/kg/day. Behavior development of newborn rats was adversely affected at all doses.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cc2f4439-7f70-45f7-8ac7-71b26fd3f930">
                     <id root="445b035b-fb61-4c95-b35d-e65d8a4d208c"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>The presence of ivermectin in human milk following topical administration of ivermectin has not been evaluated. There are no data available regarding the effects of ivermectin on milk production. Published literature suggests that ivermectin was detectable in human milk in 4 lactating women after a single 150 mcg/kg oral dose of ivermectin. However, there is insufficient information from this report to determine the effects of ivermectin on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ivermectin cream and any potential adverse effects on the breastfed infant from ivermectin cream or from the underlying maternal conditions.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_631b7502-0169-459d-9b29-06c1626af3c4">
                     <id root="0d1eb6c6-48fc-44b8-a811-12d22d28f7b3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness of ivermectin cream in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cc1c0bd7-7a29-430c-91d4-7ef27584fe4e">
                     <id root="ec626362-76ef-44da-a4fc-2f5f2201c7ac"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 1371 subjects in the two pivotal clinical studies of ivermectin cream, 170 (12.4%) were 65 and over, while 37 (2.7%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6020d872-6531-492d-a204-93cc7de14c4c">
               <id root="10f2cf1a-f2a1-455f-80d1-50d01c93795c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>In accidental or significant exposure to unknown quantities of veterinary formulations of ivermectin in humans, either by ingestion, inhalation, injection, or exposure to body surfaces, the following adverse effects have been reported most frequently: rash, edema, headache, dizziness, asthenia, nausea, vomiting, and diarrhea. Other adverse effects that have been reported include: seizure, ataxia, dyspnea, abdominal pain, paresthesia, urticaria, and contact dermatitis.</paragraph>
                  <paragraph>In case of accidental ingestion, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present. Induction of emesis and/or gastric lavage as soon as possible, followed by purgatives and other routine anti-poison measures, may be indicated if needed to prevent absorption of ingested material.</paragraph>
               </text>
               <effectiveTime value="20200413"/>
            </section>
         </component>
         <component>
            <section ID="ID_ab7d151b-1ed8-4794-b813-45a488059569">
               <id root="9655fcd4-2ec3-48a1-9b9a-ec897636c003"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Ivermectin Cream, 1% is a white to pale yellow hydrophilic cream intended for topical use. Each gram of ivermectin cream contains 10 mg of ivermectin.</paragraph>
                  <paragraph>Ivermectin is a semi-synthetic derivative isolated from the fermentation of Streptomyces avermitilis that belongs to the avermectin family of macrocyclic lactones.</paragraph>
                  <paragraph>Ivermectin is a mixture containing not less than 95.0 % and not more than 102.0 % of 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> plus 5-O-demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)-22,23-dihydroavermectin A<sub>1a</sub>, generally referred to as 22,23-dihydroavermectin B<sub>1a</sub> and B<sub>1b</sub> or H<sub>2</sub>B<sub>1a</sub> and H<sub>2</sub>B<sub>1b</sub>, respectively; and the ratio (calculated by area percentage) of component H<sub>2</sub>B<sub>1a</sub>/(H<sub>2</sub>B<sub>1a</sub> + H<sub>2</sub>B<sub>1b</sub>)) is not less than 90.0 %.</paragraph>
                  <paragraph>The respective empirical formulas of H<sub>2</sub>B<sub>1a</sub> and H<sub>2</sub>B<sub>1b</sub> are C<sub>48</sub>H<sub>74</sub>O<sub>14</sub> and C<sub>47</sub>H<sub>72</sub>O<sub>14</sub> with molecular weights of 875.10 and 861.07 respectively.</paragraph>
                  <paragraph>The structural formulas are:</paragraph>
                  <renderMultiMedia ID="id1786304678" referencedObject="c9817152-4d78-4617-967d-2cc07e542858"/>
                  <paragraph>Component H<sub>2</sub>B<sub>1a</sub>: R = C<sub>2</sub>H<sub>5</sub>, Component H<sub>2</sub>B<sub>1b</sub>: R = CH<sub>3</sub>.</paragraph>
                  <paragraph>Ivermectin cream contains the following inactive ingredients: cetyl alcohol, citric acid monohydrate, dimethicone, edetate disodium, glycerin, isopropyl palmitate, methylparaben, oleyl alcohol, phenoxyethanol, polyoxyl 20 cetostearyl ether, propylene glycol, propylparaben, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="ID_3224d471-7055-48d6-9bca-71dfed060798">
               <id root="7f67fe0b-6c1b-42b4-8978-ebe36a828b91"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20221031"/>
               <component>
                  <section ID="ID_9d1f4f8f-d495-498f-ae23-a17d25d31368">
                     <id root="9483a6fb-49e9-47e2-8881-b2ef3d882363"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>The mechanism of action of ivermectin cream in treating rosacea lesions is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_adeb516a-8430-46e7-87e2-3bfdd9fd47fb">
                     <id root="8341344d-6367-4407-b247-8efdd72cb65d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At therapeutic doses, ivermectin cream is not expected to prolong QTc interval.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f1694762-7aae-4bb3-adb6-ac4f0da7f9eb">
                     <id root="fe5da6df-0d7f-4cf7-b45a-0814c7f4994b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The absorption of ivermectin from ivermectin cream was evaluated in a clinical trial in 15 adult male and female subjects with severe papulopustular rosacea applying 1 g ivermectin cream, 1% once daily. At steady state (after 2 weeks of treatment), the highest mean ± standard deviation plasma concentrations of ivermectin peaked (T<sub>max</sub>) at 10 ± 8 hours post-dose, the maximum concentration (C<sub>max</sub>) was 2.10 ± 1.04 ng/mL (range: 0.69 - 4.02 ng/mL) and the area under the concentration curve (AUC<sub>0-24hr</sub>) was 36.14 ± 15.56 ng.hr/mL (range: 13.69-75.16 ng.hr/mL). In addition, systemic exposure assessment in longer treatment duration (Phase 3 studies) showed that there was no plasma accumulation of ivermectin over the 52-week treatment period.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>An in vitro study demonstrated that ivermectin is greater than 99% bound to plasma proteins and is bound primarily to human serum albumin. No significant binding of ivermectin to erythrocytes was observed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>In vitro studies using human hepatic microsomes and recombinant CYP450 enzymes have shown that ivermectin is primarily metabolized by CYP3A4. In vitro studies show that ivermectin at therapeutic concentrations does not inhibit the CYP450 isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 or 4A11, or induce 1A2, 2B6, 2C9 or 3A4.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>The apparent terminal half-life averaged 6.5 days (mean ± standard deviation: 155 ± 40 hours, range 92-238 hours) in patients receiving a once daily cutaneous application of ivermectin cream for 28 days.</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6eadedcc-8423-4695-b3db-20cbd60f8ad2">
               <id root="adb0d1bd-95bc-4470-a97f-542949c82652"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20221031"/>
               <component>
                  <section ID="ID_e8dcf2b2-4fa4-4fa6-a331-f35751d98d7e">
                     <id root="a356e5eb-fd62-4e7b-b6b5-aac3ccc7b3b5"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>In a 2-year dermal mouse carcinogenicity study, ivermectin was administered to CD-1 mice at topical doses of 1, 3, and 10 mg/kg/day (0.1%, 0.3% and 1% ivermectin cream applied at 2 ml/kg/day). No drug-related tumors were noted in this study up to the highest dose evaluated in this study of 10 mg/kg/day (747 times the MRHD based on AUC comparison).</paragraph>
                        <paragraph>In a 2-year oral rat carcinogenicity study, ivermectin was administered to Wistar rats at gavage doses of 1, 3, and 9 mg/kg/day. A statistically significant increase in the incidence of hepatocellular adenoma was noted in males treated with 9 mg/kg/day (1766 times the MRHD based on AUC comparison) ivermectin. The clinical relevance of this finding is unknown. No drug-related tumors were noted in females up to the highest dose evaluated in this study of 9 mg/kg/day (1959 times the MRHD based on AUC comparison). No drug-related tumors were noted in males at doses ≤ 3 mg/kg/day (599 times the MRHD based on AUC comparison).</paragraph>
                        <paragraph>Ivermectin revealed no evidence of genotoxic potential based on the results of two in vitro genotoxicity tests (the Ames test and the L5178Y/TK<sup>+/-</sup> mouse lymphoma assay) and one in vivo genotoxicity test (rat micronucleus assay).</paragraph>
                        <paragraph>In a fertility study, oral doses of 0.1, 1 and 9 mg/kg/day ivermectin were administered to male and female rats. Mortality occurred at 9 mg/kg/day (1027 times the MRHD based on AUC comparison). The precoital period was generally prolonged at 9 mg/kg/day. No treatment related effects on fertility or mating performance were noted at doses ≤ 1 mg/kg/day (68 times the MRHD based on AUC comparison).</paragraph>
                     </text>
                     <effectiveTime value="20221031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0ccaedc3-ab1b-4457-9553-bf81aade4427">
               <id root="b71ab4a8-7d99-4569-add2-943644a94d58"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>Ivermectin cream applied once daily at bedtime was evaluated in the treatment of inflammatory lesions of rosacea in two randomized, double-blind, vehicle-controlled clinical trials, which were identical in design. The trials were conducted in 1371 subjects aged 18 years and older who were treated once daily for 12 weeks with either ivermectin cream or vehicle cream.</paragraph>
                  <paragraph>Overall, 96% of subjects were Caucasian and 67% were female. Using the 5-point Investigator Global Assessment (IGA) scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe), 79% of subjects were scored as moderate (IGA=3) and 21% scored as severe (IGA= 4) at baseline.</paragraph>
                  <paragraph>The co-primary efficacy endpoints in both pivotal trials were the success rate based on the IGA outcome (percentage of subjects “clear” and “almost clear”) and absolute change from baseline in inflammatory lesion counts at Week 12. Table 1 presents the co-primary efficacy results at Week 12. Ivermectin cream was more effective than vehicle cream on the co-primary efficacy endpoints starting from 4 weeks of treatment in both studies, see Figures 1 through 4.</paragraph>
                  <table width="100%">
                     <col width="33%"/>
                     <col width="17%"/>
                     <col width="17%"/>
                     <col width="17%"/>
                     <col width="17%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="5" styleCode="Botrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Table 1: Co-Primary Efficacy Results at Week 12</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Study 1</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Study 2</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top"/>
                           <td styleCode="Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Ivermectin</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cream</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=451)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cream</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=232)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Ivermectin</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cream</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=459)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cream</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=229)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Investigator Global Assessment:</content>
                              </paragraph>
                              <paragraph>Number (%) of Subjects Clear or Almost Clear</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>173 (38.4%)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>27 (11.6%)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>184 (40.1%)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>43 (18.8%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Inflammatory Lesion Counts:</content>
                              </paragraph>
                              <paragraph>Mean Absolute (%) Change from Baseline</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>20.5 (64.9%)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>12.0 (41.6%)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>22.2 (65.7%)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>13.4 (43.4%)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <renderMultiMedia ID="id279459732" referencedObject="ee6ebaea-abce-4034-9377-156b97161365"/>
                  <renderMultiMedia ID="id-1344391577" referencedObject="bcdc13de-42d8-416b-beed-451f8bdb5e95"/>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="ID_56a5a535-9863-4bf5-b065-88f5fd3e9d7e">
               <id root="87860817-2cc9-4292-9d19-68fc85581d88"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Ivermectin Cream, 1% is a white to pale yellow cream, supplied in a laminated tube with a child resistant cap in the following sizes:</paragraph>
                  <paragraph/>
                  <list listType="unordered">
                     <item>45 gram NDC 72162-2294-2</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F)</paragraph>
                  <paragraph>[See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Repackaged/Relabeled by:<br/>Bryant Ranch Prepack, Inc.<br/>Burbank, CA 91504</paragraph>
               </text>
               <effectiveTime value="20250312"/>
            </section>
         </component>
         <component>
            <section ID="ID_9f0be9a7-83c2-45ce-8aea-4e4d2f6b42a8">
               <id root="273f91da-6082-4a40-828e-041271cd2cf8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Instructions for Use).</paragraph>
                  <paragraph>Patients using ivermectin cream should receive the following instruction:</paragraph>
                  <paragraph>Keep out of reach of children.</paragraph>
                  <paragraph>
                     <br/>Manufactured by Padagis®, Yeruham, Israel</paragraph>
                  <paragraph>www.padagis.com </paragraph>
                  <paragraph>Rev 10-22</paragraph>
                  <paragraph>3Y100 RC PH3</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="ID_ffbcc84c-d0af-4495-97ff-4c2b73280a1b">
               <id root="4f12f6fb-bbdd-4fbf-b96f-e27b4598d2f5"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Package Insert </title>
               <text>
                  <table width="540.25pt">
                     <col width="100%"/>
                     <tbody>
                        <tr styleCode="Toprule">
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> Ivermectin (eye-ver-MEK-tin) Cream, 1%</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Important: Ivermectin cream is for use on the skin only (topical use). </content>Do not use ivermectin cream in your mouth, eyes, or vagina. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">What is ivermectin cream? <br/>
                                 </content>Ivermectin cream is a prescription medicine used on the skin (topical) to treat pimples and bumps (inflammatory lesions) caused by a condition called rosacea. <br/>It is not known if ivermectin cream is safe and effective in children. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before using ivermectin cream, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if ivermectin cream will harm your unborn baby. </item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if ivermectin cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ivermectin cream. </item>
                              </list>
                              <paragraph>are breastfeeding or plan to breastfeed. It is not known if ivermectin cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use ivermectin cream. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all of the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I use ivermectin cream? <br/>See the detailed “Instructions for Use” that comes with ivermectin cream for information on how to apply ivermectin cream. </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Use ivermectin cream exactly as your healthcare provider tells you to.</item>
                                 <item>
                                    <caption>•</caption>Apply ivermectin cream to the affected areas of your face 1 time a day.</item>
                                 <item>
                                    <caption>•</caption>Avoid contact with your eyes and lips.</item>
                                 <item>
                                    <caption>•</caption>If ivermectin cream is accidentally swallowed (ingested), call your healthcare provider or go to the nearest hospital emergency room right away. </item>
                              </list>
                              <paragraph>Apply ivermectin cream to the affected areas of your face 1 time a day.</paragraph>
                              <paragraph>Avoid contact with your eyes and lips.</paragraph>
                              <paragraph>If ivermectin cream is accidentally swallowed (ingested), call your healthcare provider or go to the nearest hospital emergency room right away. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of ivermectin cream? <br/>The most common side effects of ivermectin cream include </content>skin burning sensation and skin irritation. <br/>These are not all of the possible side effects of ivermectin cream. <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br/>You may also report side effects to Padagis at 1-866-634-9120. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store ivermectin cream?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store ivermectin cream at room temperature between 68°F to 77°F (20°C to 25°C). </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep ivermectin cream and all medicines out of the reach of children. </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of ivermectin cream. <br/>
                                 </content>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ivermectin cream for a condition for which it was not prescribed. Do not give ivermectin cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ivermectin cream that is written for health professionals. </paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in ivermectin cream? <br/>Active ingredient: </content>ivermectin <br/>
                                 <content styleCode="bold">Inactive ingredients: </content>cetyl alcohol, citric acid monohydrate, dimethicone, edetate disodium, glycerin, isopropyl palmitate, methylparaben, oleyl alcohol, phenoxyethanol, polyoxyl 20 cetostearyl ether, propylene glycol, propylparaben, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol. </paragraph>
                              <paragraph>Manufactured by Padagis<sup>®</sup>
                                 <br/>Yeruham, Israel</paragraph>
                              <paragraph>www.padagis.com</paragraph>
                              <paragraph>Rev 10-22</paragraph>
                              <paragraph>For more information about ivermectin cream call 1-866-634-9120.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section ID="ID_412e609e-4b89-4a87-bb10-84ab1bf0b8bb">
               <id root="14438349-3869-46bb-a6d2-5523c3ac51c5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Instructions for Use </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Ivermectin (eye-ver-MEK-tin) Cream, 1%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important: </content>Ivermectin cream is for use on the skin only (topical use). Do not use ivermectin cream in your mouth, eyes, or vagina. Read and follow the steps below so that you use ivermectin cream correctly.</paragraph>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Open the tube of ivermectin cream by gently pressing down on the child resistant cap and twist in the direction of the arrow (counterclockwise) as shown below. See Figures A and B. To avoid spilling, do not squeeze the tube while opening or closing.</item>
                  </list>
                  <renderMultiMedia ID="id-2068799580" referencedObject="ID_2e6d00c6-4124-4dd1-9794-6f9797d249b9"/>
                  <list listType="ordered">
                     <item>
                        <caption>2.</caption>To apply ivermectin cream to your face, squeeze a pea-sized amount of ivermectin cream from the tube onto your fingertip. See Figure C.</item>
                  </list>
                  <renderMultiMedia ID="id-1470124806" referencedObject="ID_3c5332ce-5059-4e01-9d47-0cfb09b46c7e"/>
                  <list listType="ordered">
                     <item>
                        <caption>3.</caption>Apply ivermectin cream to the affected areas of your face 1 time a day. Use a pea-sized amount of ivermectin cream for each area of your face (forehead, chin, nose, each cheek) that is affected. Spread the cream smoothly and evenly in a thin layer. Avoid contact with your eyes and lips.</item>
                     <item>
                        <caption>4.</caption>To close ivermectin cream, gently press down on the child resistant cap and twist to the right (clockwise). See Figure D.</item>
                  </list>
                  <renderMultiMedia ID="id2137446337" referencedObject="ID_68b7cb9f-3011-4810-9361-0c9cd4b12d21"/>
                  <paragraph>
                     <content styleCode="bold">How should I store ivermectin cream?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Store ivermectin cream at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep ivermectin cream and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <br/>Manufactured by Padagis<sup>®</sup>
                     <br/>Yeruham, Israel</paragraph>
                  <paragraph>www.padagis.com</paragraph>
                  <paragraph>Rev 10-22</paragraph>
                  <paragraph>3Y100 RC PH3</paragraph>
               </text>
               <effectiveTime value="20221031"/>
            </section>
         </component>
         <component>
            <section>
               <id root="597ef227-1407-4a94-a222-7434a1921773"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Ivermectin Cream, 1%</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="mm63629"/>
               </text>
               <effectiveTime value="20240502"/>
               <component>
                  <observationMedia ID="mm63629">
                     <text>Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl721622294.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>